VEGFC and Chronic colitis: However, our data were in contrast with otherstudies demonstrating that 1) systemic delivery of VEGF-C provided significantprotection against inflammation in a DSS model of acute and chronic colitis (29); 2) VEGFR-3 blockade significantly reducedlymphatic vessel density, while significantly increasing inflammatory edema formationand inhibiting disease resolution (29); 3)transgenic delivery of VEGF-C/-D significantly induced lymphangiogenesis (30), and limited acute skin inflammation viaenhanced lymphatic drainage and reduction of edema formation (31).